NEUROCRINE BIOSCIENCES INC

Nasdaq: NBIX

Biological Products, (No Diagnostic Substances) · Entity-resolved by Clous

CIK0000914475

TickerNBIX

ExchangeNasdaq

SIC2836

StateDE

FY end12-31

Key financials

RevenueFY2025-12-31

$2.86B

+21.4% YoY

Net IncomeFY2025-12-31

$478.6M

+40.2% YoY

Total AssetsFY2025-12-31

$4.63B

+24.5% YoY

EquityFY2025-12-31

$3.25B

+25.6% YoY

Shares OutstandingFY2025-12-31

100.36M

—

Operating Cash FlowFY2025-12-31

$782.7M

+31.5% YoY

AI business summary — latest 10-K

Summary

The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.

What it means

Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).

What to watch

Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.

Generated from public filings · not investment advice

Concept	FY2022-12-31	FY2023-12-31	FY2024-12-31	FY2025-12-31	YoY	% rev
Revenue	$1.49B	$1.89B	$2.36B	$2.86B	+21.4%	100%
Net Income	$154.5M	$249.7M	$341.3M	$478.6M	+40.2%	17%
Total Assets	$2.37B	$3.25B	$3.72B	$4.63B	+24.5%	162%
Equity	$1.71B	$2.23B	$2.59B	$3.25B	+25.6%	114%
Operating Cash Flow	$339.4M	$389.9M	$595.4M	$782.7M	+31.5%	27%
Shares Outstanding	—	—	—	100.36M	—	—

Get this entity — and 970.89K+ others — programmatically.

One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.

GET /v1/entities?cik=0000914475